Adlai Nortye Announces $140.0 Million Private Placement Equity Financing

Core Viewpoint - Adlai Nortye Ltd. has announced a private investment in public equity financing expected to generate approximately $140 million in gross proceeds, aimed at supporting its innovative cancer therapies [1][3]. Group 1: Financing Details - The company is selling 64,615,386 Class A ordinary shares at a price of $2.1667 per share, equivalent to $6.50 per American Depositary Share (ADS) [2]. - The private placement is co-led by Cormorant Asset Management and Columbia Threadneedle Investments, with participation from both new and existing investors, including Balyasny Asset Management L.P. and Point72 [3]. - Approximately $55 million of Class A ordinary shares will be sold to entities controlled by Yang Lu, the Chairman and CEO of the company [3]. Group 2: Company Overview - Adlai Nortye is a clinical-stage biotechnology company focused on developing innovative cancer therapies, leveraging its R&D presence in the U.S. and China [7]. - The company is building a pipeline of drug candidates in two key areas: next-generation cancer immunotherapies and RAS-targeting therapies [7]. - Key drug candidates include AN8025, a tri-functional fusion protein, and AN4005, a first-in-class oral small-molecule PD-L1 inhibitor, aimed at activating cancer immunity [7].